aggregators. In vivo IQCA-TAVV targeted arterial thrombus, dose dependently inhibited arterial thrombosis with a 1 nmol/kg of minimal effective dose, and the activity waŝ1670 folds of that of aspirin. CONCLUSION IQCA-TAVV represented the design, preparation and application of nanomedicine capable of adhering on the surface of activated platelets, attenuating platelet activation, targeting arterial thrombus and
背景技术动脉血栓形成与一系列病理状况有关,动脉血栓形成
抑制剂的发现具有临床意义。方法通过分析抗血小板药物、血栓靶向肽和抗血栓纳米系统3S-1,2,3,4-
四氢异喹啉-3-羰基-Thr-Ala-Arg-Gly-Asp(Val)的药效团)-Val (IQCA-TAVV) 被设计和制备为纳米级动脉血栓形成
抑制剂。结果 IQCA-TAVV纳米粒在体外能够粘附在活化血小板表面,减弱活化血小板以延长伪足,抑制活化血小板形成聚集体。体内IQCA-TAVV靶向动脉血栓,以1 nmol/kg的最小有效剂量剂量依赖性抑制动脉血栓形成,活性是
阿司匹林的1670倍。